Jointly provided by the University of Chicago Pritzker School of Medicine and RedMedEd
Support for this activity has been provided through an independent educational grant from Pfizer.
Although the introduction of biologic agents has transformed treatment paradigms for rheumatoid arthritis (RA), a considerable proportion of patients do not respond sufficiently to these therapies. A potential new therapeutic alternative for these patients is small-molecule inhibitors, which offer targeted inhibition of intracellular pathways that can be achieved via oral administration. To realize the benefits of small-molecule inhibitor therapy, it is essential for clinicians to know how these agents target cytokine signaling and intracellular pathways.
This activity contains three interactive modules designed to help clinicians understand the mechanisms of action of small-molecule inhibitors and recognize how these agents fit into established RA management guidelines.
This activity has been designed to meet the educational needs of rheumatologists and other healthcare providers who are involved in the care of patients with RA.
Upon completion of this activity, participants should be able to:
Describe the role of cytokine signals and pathways in driving inflammation in RA
Summarize the differences between small-molecule inhibitors and biologics in RA treatment
Evaluate recent clinical advances with the use of small-molecule inhibitors for RA and their potential implications for clinical practice
Conflict Of Interest Disclosure Policy
According to the disclosure policy of the University of Chicago Pritzker School of Medicine, all faculty, planning committee members, and other individuals who are in a position to control content are required to disclose any relevant relationships with any commercial interests related to this activity. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation. All educational materials are reviewed for fair balance, scientific objectivity and levels of evidence.
Anisha B. Dua, MD, MPH—Program Chair Assistant Professor, Department of Rheumatology Fellowship Program Director Director of the Vasculitis Center University of Chicago Chicago, IL
Dr. Dua has disclosed the following relevant financial relationships: Principal Investigator: ChemoCentryx
Eric M. Ruderman, MD Professor of Medicine Associate Chief, Clinical Affairs Division of Rheumatology Feinberg School of Medicine Clinical Practice Director Northwestern Medical Faculty Foundation Chicago, IL
Dr. Ruderman has disclosed the following relevant financial relationships: Consultant: AbbVie, Amgen, Bristol-Myers Squibb, Janssen, Lilly, Novartis, Pfizer, Roche, Seattle Genetics
Mary Chester M. Wasko, MD Clinical Professor of Medicine Temple University School of Medicine Division Director, Rheumatology Philadelphia, PA
Dr. Wasko has disclosed the following relevant financial relationships: Principal Investigator: Amgen, AstraZeneca, Bristol-Myers Squibb, UCB
Accredited Provider Disclosure
The University of Chicago Mahira Z. Bonomo, MBA, Director Continuing Medical Education, has disclosed no relevant financial relationships.
Publishing Staff Disclosure
RedMedEd Denise C. LaTemple, PhD, Director of Scientific Services, has disclosed no relevant financial relationships. Jonathan S. Simmons, ELS, Senior Managing Editor, has disclosed no relevant financial relationships. Karen Smith, Creative Director, has disclosed no relevant financial relationships. Karen Tenaglia, Project Manager, has disclosed no relevant financial relationships. Barbara Zosh, Director of Operations, has disclosed no relevant financial relationships.
AMA PRA Category 1 Credit(s)TM
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Chicago Pritzker School of Medicine and RedMedEd. The University of Chicago Pritzker School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
The University of Chicago Pritzker School of Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. RedMedEd, the University of Chicago Pritzker School of Medicine, and Pfizer do not recommend the use of any agent outside the labeled indications.
The information presented in this activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician regarding diagnosis and treatment of a specific patient’s medical condition.
The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of RedMedEd, the University of Chicago Pritzker School of Medicine, or Pfizer. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
There are no fees to participate in the activity. Participants must review all activity information, including the learning objectives, disclosure statements, and content. To receive CME credit for participation, participants must complete the posttest (achieving a passing grade of 80% or greater) and program evaluation. Certificates can be printed immediately.
For questions regarding CME credit, contact the University of Chicago Pritzker School of Medicine at (773) 702-1056 or firstname.lastname@example.org.
For technical questions related to this activity, please contact RedMedEd at (610) 251-6841 or email@example.com.
Apple iPad or iPad mini (iOS 8 or higher) with an Internet connection
A computer with an Internet connection
Internet browser: Google Chrome, Internet Explorer 9 or higher, Firefox 26 or higher, or Safari 5 or higher
Additional software: Adobe Flash Player and/or an HTML 5-capable browser is required for video or audio playback; Adobe Acrobat Reader may occasionally be required